Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02094872 · ClinicalTrials.gov registry record · Phase 2
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT02094872 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 49 participants.
The verdict
NCT02094872, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. Molecularly targeted therapy works by treating patients with substances that kill cancer cells by targeting key molecules involved in cancer cell growth.
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
- OTHER quality-of-life assessment
- PROCEDURE therapeutic procedure
- DRUG MEK 162 therapy or molecularly targeted therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02094872
The ClinicalTrials.gov registry entry for NCT02094872 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT02094872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02094872 about?
NCT02094872 is a clinical study titled "Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic". This phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances to...
What is the current status of trial NCT02094872?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2014-05. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02094872?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER), quality-of-life assessment (OTHER), therapeutic procedure (PROCEDURE), MEK 162 therapy or molecularly targeted therapy (DRUG).
Who is sponsoring clinical trial NCT02094872?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.